Cipher, Edesa Biotech deal

Cipher granted Edesa rights to ASF-1096 to treat anorectal disorders.

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE